

Dose equivalence and conversion

4 oral drops (8 mg) is equivalent in therapeutic effect to 10 mg tablet.

Important safety information

For all SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS

MHRA/CHM advice: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (January 2021)

SSRIs are known to increase the risk of bleeding due to their effect on platelet function. An EU review of observational data found a slightly increased risk of postpartum haemorrhage associated with the use of SSRIs during the month before delivery. This risk may be significant in patients with other risk factors for bleeding disorders.

Healthcare professionals should continue to consider the benefits and risks of antidepressant therapy (particularly in the later stages of pregnancy), and the risks of untreated depression, during pregnancy. Anticoagulant medication in women at high risk of thrombotic events should not be stopped, however, prescribers should be aware of the risk identified.

Contra-indications

For all SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS

Poorly controlled epilepsy; SSRIs should not be used if the patient enters a manic phase